Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis

Table 1 Characteristics of the included RCT studies^a

	n ^b	GPI, %	Age, y	Male	Hypertension	DM	Dyslipidemia	Smoking	FU
Brener, et al., 2014 [1]	452	50	57.6 ± 10.4/62.7 ± 12.7	79.4/71	24.5/35.0	9.7/12.1	16.8/15.2	68.8/58.3	1 y
Christ, et al., 2013 [5]	56	100	57 ± 11/67 ± 13	74/88	48/77	28/39	84/94	60/58	1 mo
PLATO, 2009 [3]	7026 ^c	26	62/62 ^d	71.6/71.7	65.8/65.1	24.9/25.1	46.6/46.7	N/A	1 y
Michelle, 2009 [2]	3534 ^c	54.5	60/60 ^d	76.7/75	61.2/61.7	22.7/22.3	56.4/57.2	N/A	1 mo
BRAVE, 2014 [6]	548	4	51.9–71.7/52.9–71.5	76/79	66/64	17/15	57/51	57/67	1 mo
FABOLUS PRO, 2012 [4]	100	48	66 ± 11/67 ± 10	69/78	63/79	19/21	50/64	N/A	1 mo
Yang, 2015 [13]	158	66.5	60.6 ± 7.7	42%	67.3	100	N/A	28.85–38.85	1 mo

^a Reported as percentage, unless noted otherwise; ^b subjects; ^c STEMI; ^d median age, risks factor are from the TAPT cohorts
Abbreviations: DM diabetes mellitus; FU follow-up

ISSN: 1471-2261